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S u m m a r y
Introduction. Vascular calcifications in patients with end stage renal disease on mainte-
nance hemodialysis is the leading cause of cardiovascular events and death. Epidemiologi-
cal studies have shown that severe vascular calcifications and associated increased risk of 
morbidity and mortality occur particularly in patients with reduced serum fetuin-A levels.
Aim. The aim of the study was to assess the severity of calcifications in the cardiovas-
cular system of patients treated with repeated hemodialysis depending on the concentra-
tions of serum fetuin-A, bone mineral density (BMD) and markers of inflammation.
Material and methods. The study was performed in 71 patients (31 women, 40 men) 
aged 60 ± 12 years on chronic dialysis because of end-stage renal failure for a period 
of approximately 75 ± 57.2 months. The level of vascular calcifications was examined 
based on coronary artery calcification score (CaSc) and common carotid artery intima-
media thickness (CCA-IMT). Bone mineral density was measured using Lunar DPX. The 
serum concentrations of routine laboratory test were performed based on Modular P ana-
lyzer (Roche Diagnostics), iPTH using Nichols method, hsCRP and IL-6 using nephelo-
metric techniques while fetuin A, was measured using commercially available ELISA kits.
Results. Densitometry showed a decrease in bone mineral density both within the ranks 
of the femur (Tscore = -2.10 ± 1.00) and lumbar spine (Tscore = -1.03 ± 1.51). Calcium 
scoring performed in patients showed severe calcification; CaSc – 511 (158-2394) Agatston 
units and the CCA-IMT was 0.90 ± 0.42. Fetuin-A concentrations were significantly neg-
atively associated with patients age (r = -0.26, p = 0.04), log (iPTH) (r = -0.31, p = 0.02), 
log (CRP) (r= -0.31, p = 0.02), log (IL-6) (r = -0.41, p = 0.001), log (CaSc) (r = -0.29, p = 0.03) 
and log (CCA-IMT) (r = -0.28, p = 0.04). Concentrations of fetuin-A were positively correlated 
with albumin (r = 0.37, p = 0.003) and BMD in the region of femoral neck (r = 0.26, p = 0.04).
Conclusions. Patients on maintenance hemodialysis suffer from severe calcifications 
of vascular system. Low serum fetuin-A levels are negatively associated with calcification 
parameters, inflammation and hyperparathyroidism.
S t r e s z c z e n i e
Wstęp. Zwapnienia naczyniowe u pacjentów ze schyłkową niewydolnością nerek le-
czonych powtarzanymi hemodializami są główną przyczyną zdarzeń sercowo-naczynio-
wych i zgonów. W badaniach epidemiologicznych wykazano, że duże zwapnienia na-
czyniowe i związane z nimi ryzyko chorobowości i śmiertelności występują szczególnie 
u chorych z niskimi stężeniami fetuiny-A w surowicy.
Cel pracy. Celem badania była ocena nasilenia zwapnień w układzie sercowo-naczy-
niowym u chorych leczonych powtarzanymi hemodializami w zależności od stężenia w su-
rowicy fetuiny-A, gęstości mineralnej kości (BMD) i wskaźników zapalenia.
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INTRODUCTION
Cardiovascular diseases are the leading cause of death 
in the population of patients with end stage renal disease 
on maintenance hemodialysis. The increased cardiovas-
cular mortality in dialysis patients may be influenced by 
many factors, such as advanced age, atherosclerosis, 
chronic inflammation, malnutrition, hypertension, anemia, 
diabetes, left ventricular hypertrophy (LVH) and vascular 
calcification in the course of secondary hyperparathyroid-
ism (1-3). Vascular calcifications may be observed even in 
the early decades of life in patients with end-stage renal 
disease (ESRD) and severity of calcification increases with 
the progression of renal failure (2-6).
Epidemiological studies have shown that severe 
vascular calcifications and associated increased risk 
of mortality occur particularly in patients with reduced 
serum fetuin-A levels (7-9). The fetuin-A acts as an in-
hibitor of extraosseous calcification (10-14), it inhibits 
the de novo formation of hydroxyapatite crystals, at 
least in part, causing the sequestration of calcium and 
phosphate, and preventing their precipitation in serum 
containing these minerals (12, 15). The fetuin-A accu-
mulates in the vascular calcification (16) and its serum 
levels reduction in patients with ESRD is inversely cor-
related with the occurrence of calcification of the coro-
nary arteries (17-20).
It was also found that in patients with ESRD calcified 
plaques were higher in those with low bone density (21). 
It was also demonstrated that reduced bone mineral-
ization in patients with chronic kidney disease (CKD), 
or in post-menopausal women are accompanied with 
increased calcifications of tissues, especially vascular 
system (22-24).
AIM
The aim of the study was to assess the severity of 
calcifications in the cardiovascular system in patients 
treated with repeated hemodialysis depending on the 
concentrations of serum fetuin-A, bone mineral density 
and markers of inflammation.
MATERIAL AND METHODS
The study included 71 patients (31 women, 40 men) 
aged 60 ± 12 years on chronic dialysis because of 
end-stage renal failure for a period of approximately 
75 ± 57.2 months. The cause of ESRD was chronic 
glomerulonephritis – 16 patients, chronic pyelonephri-
tis – 16, kidney cirrhosis – 18, polycystic kidney dis-
ease – 10, diabetic nephropathy – 3 and not known 
cause of ESRD – 8. From the study group 55 patients 
had been treated for hypertension, and 8 had diabetes 
mellitus type 2. None of the patients had an active in-
fections at the time of the study.
In 35 patients ischemic heart disease was diag-
nosed.
The basic demographic data and the results obtained 
are shown in table 1. Blood samples for routine labo-
ratory tests were taken before hemodialysis start in the 
middle of the week sessions. The basic biochemical 
studies have been performed on the analyzer Modu-
lar P (Roche Diagnostic), C-reactive protein and IL-6 us-
ing immunonephelometric techniques Behring Nephe-
lometer II, Dade Behring, Marburg, Germany while iPTH 
based on chemiluminescence Nichols method. The 
serum concentration of fetuin-A were measured using 
commercially available ELISA kits. Blood samples were 
centrifuged and the resulting serum/plasma aliquoted 
and stored at -70°C until immunoassays measurement. 
Routine laboratory tests were performed in the Diagnos-
tic Laboratory at the University Hospital in Kraków, and 
immunochemical tests in Diagnostics Department, Jagi-
ellonian University Medical College in Kraków.
The study was approved by the Jagiellonian Univer-
sity Bioethics Committee and all the patients gave writ-
ten informed consent for participation.
Imaging techniques
The calcification score was measured by 64-slice 
spiral computer tomography scans, MSCT (Siemens 
Medical Solutions Inc., Germany) using the standard 
calcium scoring protocol. To quantify the calcification 
Materiał i metody. Badania przeprowadzono w grupie 71 pacjentów (31 kobiet, 
40 mężczyzn) w wieku 60 ± 12 lat leczonych powtarzanymi dializami z powodu schyłkowej 
niewydolności nerek przez okres 75 ± 57,2 miesiąca. Nasilenie zwapnień w naczyniach 
oceniano w oparciu o wskaźnik uwapnienia naczyń wieńcowych (CaSc) i grubość kom-
pleksu błony wewnętrznej i środkowej tętnicy szyjnej wspólnej (CCA-IMT). Gęstość mine-
ralną kości mierzono przy użyciu aparatu Lunar DPX. Stężenie w surowicy rutynowo ba-
danych wskaźników oceniano w aparacie Modular P analyzer (Roche Diagnostics), iPTH 
w oparciu o metodę Nicholsa, hsCRP i IL-6 przy użyciu techniki nefelometrycznej, podczas 
gdy fetuinę-A oznaczano w oparciu o zestawy ELISA.
Wyniki. W badaniu densytometrycznym wykazano obniżoną gęstość w zakresie kości 
udowej (Tscore = -2,0 ± 1,00) i odcinka lędźwiowego kręgosłupa (Tscore = -1,03 ± 1,51). 
Wskaźnik uwapnienia wskazywał na nasilone zwapnienia; CaSc – 511 (158-2394) jed-
nostek Agatstona, a CCA-IMT – 0,90 ± 0,42. Stężenia fetuiny-A były istotnie ujemnie 
związane z wiekiem pacjentów (r = -0,26; p = 0,04), log (iPTH) (r = -0,31; p = 0,02), 
log (CRP) (r= -0.31, p = 0.02), log (IL-6) (r = -0.41, p = 0.001), log (CaSc) (r = -0,29; 
p = 0,03) i log (CCA-IMT) (r = -0,28; p = 0,04). Stężenia fetuiny-A dodatnio korelowały 
z albuminą (r = 0,37; p = 0,003) i BMD w okolicy szyjki kości udowej (r = 0,26; p = 0,04).
Wnioski. Pacjenci leczeni powtarzanymi hemodializami mają zaawansowane zwapnie-
nia w układzie naczyniowym. Niskie stężenia fetuiny-A w surowicy są ujemnie związane ze 
wskaźnikami uwapnienia, zapaleniem i nadczynnością przytarczyc.
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of the coronary arteries indicator of coronary artery 
calcification was used, expressed in units of numerical 
values  forming the sum of the Agatston score for final 
calcification of the coronary arteries (CaSc). Common 
carotid artery intima-media thickness (CCA-IMT) mea-
surements were performed using a ALOKA 5500 SV 
equipped with a head for vascular studies. The CCA-IMT 
of the medial trunk-internal carotid artery was measured 
at three locations: at the height of half the length of 
the common carotid artery; at a distance of 1 cm from 
the bifurcation of the common carotid artery and at the 
height of the pad common carotid artery. In each of 
the three points a 2-3 medial thickness measurements 
during the diastolic phase of the cardiac cycle were 
performed, and the final results were calculated as an 
average arithmetic values at a point of measurement. 
Both, CaSc and CCA-IMT were performed at the Center 
for Diagnosis and Rehabilitation of Heart and Lung Dis-
eases Specialist Pope John Paul II Hospital in Kraków.
Bone mineral density (BMD) was performed in the 
Metabolic Diseases Clinic of the University Hospital in 
Kraków using Dual Energy X-ray Absorptiometry, Lunar 
DPX (Lunar, USA). BMD was measured in the lumbar 
spine (L1-L4) and femoral region (Ward’s triangle).
Statistical analysis
The obtained data were reported as number (per-
cent) and analyzed with Chi-squared test. Mean ± stan-
dard deviation (SD) or median (Lower-upper quartile) 
according distribution were given. Simple and multiple 
regression models were computed after log10-trans-
formation of right-skewed variables.
The results were considered significant at p ≤ 0.05.
RESULTS
The results of routine laboratory parameters, concen-
tration of fetuin-A and imaging studies in the analyzed 
group of patients are summarized in table 1. Densitom-
etry showed a decrease in bone mineral density both 
within the ranks of the femur (Tscore = -2.10 ± 1.00) 
and lumbar spine (Tscore = -1.03 ± 1.51). Calcium 
scoring performed in patients showed severe calcifica-
tion of the vascular system, CaSc – 511 (158-2394) Ag-
atston units and the CCA-IMT was 0.90 ± 0.42.
To evaluate the relationships of fetuin-A with se-
lected variables the linear correlation tests were per-
formed (tab. 2). In these tests fetuin-A concentrations 
were significantly negatively associated with pa-
tients age (r = -0.26, p = 0.04), log (iPTH) (r = -0.31, 
p = 0.02), (CRP) (r= -0.31, p = 0.02), log (IL-6) (r = -0.41, 
p = 0.001), log (CaSc) (r = -0.29, p = 0.03) and log (CCA-
IMT) (r = -0.28, p = 0.04). Concentrations of fetuin-
A were positively correlated with albumin (r = 0.37, 
p = 0.003) and BMD femoral neck (r = 0.26, p = 0.04).
Tab. 2. Selected laboratory values and correlation of fetuin-A 
with studied parameters (the Pearson`s correlation coefficient)
Parameters
Concentrations 
of laboratory 
parameters
Entire cohort
r p
Age (years) -0.26* 0.04*
Calcium (mmol/L) 2.30 ± 0.22 0.13 0.3
Phosphate (mmol/L) 1.87 ± 0.53 -0.24 0.07
Ca x Pi (mg2/dl2) 52.7 ± 15.11 -0.19 0.1
Log (iPTH) (pg/ml) 378 (132-1035) -0.31* 0.02*
Albumin (g/L) 38.9 ± 3.4 0.37* 0.003*
Log (CRP) (mg/L) 5.71 (2.17-10.80) -0.31* 0.02*
Log (IL-6) (pg/ml) 4.84 (0.70-7.25) -0.41* 0.001*
BMD femoral neck (g/cm2) 0.26* 0.04*
BMD lumbar spine (g/cm2) 0.09 0.5
Log (CaSc) (Agatstone units) -0.29* 0.03*
Log (CCA-IMT) (mm) -0.28* 0.04*
Values that were normally distributed, expressed as mean ± SD, data that 
were not normally distributed, expressed as median and (minimum-maxi-
mum). Parameters that were not normally distributed were log10-transfor-
med for analysis. *Significant associations
Ca x Pi – calcium phosphate product; iPTH – intact parathormone; CRP 
– C-reactive protein; IL-6 – interleukin-6; BMD – bone mineral density; 
CaSc – calcium scoring; CCA-IMT – common carotid artery intima-media 
thickness
In next step of our analysis we tent to investigate 
differences in relations between fetuin-A levels and 
analyzed parameters in women and men separately. 
Tab. 1. Demographic and clinical data of hemodialysis patients
Studied parameters Whole group (N = 71) Women (N = 31) Men (N = 40) p-value
Age (years) 60 ± 12 61 ± 14 59 ± 12 0.5
Dialysis vintage (months) 60 (36-100) 52 (30-108) 60 (45-97) 0.8
BMI (kg/m2) 23.6 (21.0-26.7) 22.0 (20.0-25.5) 24.8 (22.6-28.0) 0.01*
Hypertension 55 (77%) 23 (74%) 32 (80%) 0.6
Diabetes mellitus type 2 8 (11%) 2 (6%) 6 (15%) 0.5
Ischemic heart disease 35 (49%) 19 (61%) 16 (40%) 0.08
Smoking 15 (21%) 5 (16%) 10 (25%) 0.4
BMD femoral neck (g/cm2) 0.77 ± 0.17 0.73 ± 0.16 0.81 ± 0.17 0.07
BMD lumbar spine (g/cm2) 1.08 ± 0.24 0.96 ± 0.20 1.17 ± 0.23 0.0004*
CaSc (Agatstone units) 488 (109-1853) 462 (41-1428) 511 (158-2394) 0.5
CCA-IMT (mm) 0.90 (0.80-1.05) 0.90 (0.75-1.00) 0.90 (0.80-1.05) 0.3
Values that were normally distributed, expressed as mean ± SD, data that were not normally distributed, expressed as median and (minimum-maxi-
mum), categorical variables are presented as %. *Significant associations
BM – body mass index; BMD – bone mineral density; CaSc – calcium scoring; CCA-IMT – common carotid artery intima-media thickness
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In the male group fetuin-A were significantly positively 
associated with levels of albumin (r = 51, p = 0.0008), 
negatively with levels of log (CRP) (r = -0.41, p = 0.008) 
and of IL-6 (r = -0.52, p = 0.0006). However no sig-
nificant associations were observed between fetuin-A 
concentrations and the same inflammation parame-
ters in female group (fig. 1). Additionally we observed 
that in male group the relationships between fetuin-A 
and inflammation markers are stronger than in whole 
patients group. When analyzed associations between 
fetuin-A and bone parameters depending on sex we 
showed that only in female group we observed statis-
tically significant negative correlation between fetuin-
A and log (iPTH) (r = -0.40, p = 0.03).
Relationships between fetuin-A and log (CaSc) re-
mained only in male group, r = -0.36, p = 0.03 (fig. 2), 
and additionally between fetuin-A and log (CCA-IMT) 
lost their significance in both groups.
Correlation between fetuin-A levels and BMD of fem-
oral neck almost reach statistical significance in men; 
r = 0.33, p = 0.06 (fig. 3).
Because CKD is accompanied by secondary hyper-
parathyroidism expressed by high levels of iPTH and 
chronic generalized inflammation we analyzed the extent 
to which correlate with serum fetuin-A. The study group 
of patients was divided into a group with serum iPTH 
≤ 300 pg/ml and group with secondary hyperparathyroid-
ism with iPTH > 300 pg/ml, and a group with low CRP 
Fig. 1. Linear correlations of fetuin-A levels with albumin, log (CRP) and log (IL-6). A, C, E represents correlations in women. B, D, F rep-
resents correlations in men
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≤ 10 mg/L and CRP > 10 mg/L (fig. 4). Both secondary hy-
perparathyroidism (p = 0.03) and inflammation (p = 0.01) 
were associated with decreased levels of fetuin-A in se-
rum of patients on hemodialysis.
As the renal disease is accompanied by disorders of 
bone metabolism as a result of renal bone disease we 
tested using multiple regression model fetuin-A, CRP and 
PTH with bone mineral density. It has been shown that in 
the presence of PTH (model I), fetuin-A loses significance 
in relation to BMD, and when included in the analysis 
CRP (model II), fetuin-A remained an independent predic-
tor of reduced bone mass in hemodialysis patients (tab. 3).
Based on the multiple regression analysis for fetuin-A as 
the dependent variable has been shown that in patients 
on hemodialysis, CRP is independent of PTH predictor of 
reduced levels of fetuin-A (tab. 4).
Tab. 3. Multiple regression models for femoral neck BMD as 
the dependent variable
The explanatory 
variables
Model I Model II
beta p beta p
Fetuin-A 0.20 0.1 0.32* 0.02*
log (CRP) – – 0.05 0.7
log (iPTH) -0.28* 0.03* – –
*Statistically significant
Tab. 4. Multiple regression models for fetuin-A as the depen-
dent variable
The explanatory 
variables
Model III Model IV
beta p beta p
log (CRP) -0.29* 0.01* -0.29* 0.01*
log (iPTH) -0.22 0.06 -0.13 0.4
*Statistically significant
DISCUSSION
The main findings of this cross-sectional study per-
formed in in the group of ESRD patients on mainte-
nance hemodialysis are as follows:
1. Diminished serum levels of fetuin-A in hemodial-
ysed patients was both associated with the extent 
of CaSc and CCA-IMT.
2. The serum fetuin-A levels were negatively associ-
ated both with inflammation expressed as increased 
serum hsCRP levels and IL-6 as well as secondary 
hyperparathyroidism with high iPTH serum levels.
3. Fetuin-A levels showed negative correlation with 
inflammatory parameters only in men, but in 
women it correlates only with log (iPTH).
4. The serum fetuin-A levels correlated positively 
with BMD of the femoral neck but not BMD of 
Fig. 2. Linear correlations of fetuin-A levels with log (CaSc) in women (A) and in men (B)
Fig. 3. Linear correlations of fetuin-A levels with femoral neck BMD in women (A) and in men (B)
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lumbar spine, and in relation to the femoral neck 
BMD low fetuin-A was dependent of PTH, but 
independent of CRP associated with decreased 
bone mass.
In our study we found that reduced levels of fetuin-A 
correlated with the severity of coronary artery calcifica-
tion expressed as CaSc and CCA-IMT.
Cardiovascular disease is the most common cause 
of mortality in hemodialysis patients, in whom cardio-
vascular mortality increased 10-20 times compared to 
the general population (25). High values of coronary 
artery calcifications expressed as CaSc obtained in 
patients on hemodialysis, and thickening of the intima-
media layers, can indicate the presence of a high risk 
of cardiovascular morbidity in the study group. At the 
same time there was decrease in bone mineral density, 
which in ESRD patients is an expression of renal os-
teodystrophy.
Coronary calcifications documented in patients 
with ESRD patients, the severity of the atherosclerotic 
vascular diseases are predictors of cardiovascular 
events (2, 3). Both the changes observed in clinical 
imaging of arteries, hyperphosphatemia and bone 
metabolism disturbances as a results of secondary 
hyperparathyroidism in conjunction with chronic in-
flammatory process, are the risk factors for increased 
morbidity and cardiovascular mortality in this group of 
patients (26, 27).
Although, vascular calcification occurs in most pa-
tients with CKD, some patients do not develop calci-
fication, despite exposure to the uremic environment. 
Physiological calcification inhibitors, among which an 
important is fetuin-A, may play a role in inhibiting the 
formation and progression of metastatic calcification 
but the results of clinical trials are few and often con-
tradictory. Several researchers have observed a rela-
tionship between low levels of fetuin-A and vascular 
calcification (12, 19, 28-30), although others found no 
similar relationship (31, 32), as there was no relation-
ship between levels of fetuin-A and CaSc in predialysis 
patients (33). Vascular calcification leads to stiffening 
of the arteries. Fetuin-A endogenous inhibitor of vascu-
lar calcification is associated with arterial stiffness and 
mortality in dialysis patients without diabetes (34) and 
in patients in the predialysis stage (35). In contrast, Her-
mans et al. (32) showed no differences between serum 
fetuin-A of dialysis group and normal healthy control 
subjects, and showed no relationship between serum 
fetuin-A and arterial stiffness. In the general population 
findings are inconsistent, because fetuin-A levels were 
positively associated with CaSc in patients not under-
going dialysis with diabetic nephropathy (31). Based on 
epidemiological studies it was found that fetuin-A acts 
as an inhibitor of systemic ectopic calcification (14), but 
the clinical significance of the concentration of fetuin-A 
is not entirely clear. Although a multicenter prospec-
tive study involving patients with HD and PD showed 
that the concentration of fetuin-A may be a predictor of 
overall mortality in dialysis patients (36, 37). Similarly it 
was shown a significant association between reduced 
levels of fetuin-A and calcification of heart valve, athero-
sclerosis, malnutrition and inflammation and has been 
associated with mortality and cardiovascular events in 
PD patients (9, 29, 38, 39).
The relationship between serum fetuin-A levels 
and BMD has already been confirmed, particularly 
Fig. 4. (A) Serum fetuin-A concentration in relation to secondary hyperparathyroidism, defined as concentrations iPTH > 300 pg/ml. (B) Se-
rum fetuin-A concentration in relation to inflammation, defined as concentrations CRP > 10 mg/L. Data are shown as median, interquartile 
range (box) and minimum-maximum (whisker). Open circles represent row data
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in hemodialysis patients in whom renal osteodys-
trophy coexists with vascular calcification (40-44). 
Numerous studies indicate a high similarity of the 
pathophysiological mechanisms responsible for the 
progression of vascular calcification plaque to the 
process of bone formation. It was also found that 
higher levels of fetuin-A are significantly associated 
with higher BMD total hip, lumbar spine, and whole 
body bone mineral density among well functioning 
community-dwelling older women (45). Calcification 
and plaque volume were higher in patients whose 
T-score < -2.5 in the region of proximal radius, 
neck and trochanter of the femur and lumbar spine. 
CaSc, weight and volume of plaque in the coronary 
arteries were significantly correlated with serum fe-
tuin-A, BMD and T-score proximal radius, neck, tro-
chanter of the femur, but not with the lumbar spine. 
It was also shown a relationship between serum fe-
tuin A levels, CaSc, CCA-IMT, cardiovascular events 
and BMD in chronic hemodialysis patients (21, 42, 
46, 47). In patients with ESRD on HD apparently rate 
of bone turnover depends largely on the concen-
tration of circulating parathyroid hormone and it is 
a major determinant of BMD in this patients, and the 
relationship between serum fetuin-A levels and BMD 
is associated with hyperparathyroidism (48, 49). Re-
nal osteodystrophy accompanying CKD is associ-
ated with an increase in PTH, CRP and reduction of 
bone mineral density (7, 30, 43, 49).
It has been shown in our study that the reduced 
concentrations of fetuin-A is accompanied with re-
duced bone mass − BMD of femoral neck. In ad-
dition, we examined the relationship between BMD 
and fetuin-A in a model of multiple regression analy-
sis. In this model it was shown that fetuin-A in the 
presence of PTH loses significance in relation to 
BMD, however in the presence of CRP (model II), 
fetuin-A remained an independent predictor of re-
duced bone mass in hemodialysis patients. The re-
sults may indicate the role of fetuin-A in maintain-
ing normal bone mass, and that her relationship 
with bone mass depends on the secondary hyper-
parathyroidismus, and perhaps accelerated bone 
turnover in these patients. These observations was 
confirmed by the multiple regression determinants 
analysis of fetuin-A in serum of patients on hemodi-
alysis. It has been shown that independent predictor 
of the concentrations of fetuin-A, CRP, and skeletal 
parameters exert their effect on fetuin-A in a man-
ner dependent from each other. So accelerated 
bone turnover, caused an increase in PTH and an 
increased release of bone markers is accompanied 
by lowering levels of fetuin-A levels in hemodialy-
sis patients. When studied group of patients were 
divided into subgroups according to the iPTH and 
CRP we showed that in patients undergoing hemo-
dialysis, both chronic inflammation and secondary 
hyperparathyroidism are associated with decreased 
levels of fetuin-A.
In our study we observed lack association of fetuin-A 
with CaSc, and BMD femoral neck in women. It is pos-
sible that in women dependent of sex factors had an in-
fluence on relation of fetuin-A, to other variables. It was 
shown in other study that the concentrations of fetuin A 
did not differ between men and women (50). Fetuin-A 
is the major bone non non-collagenous protein. In vitro 
fetuin A can inhibit or stimulate osteogenesis, depend-
ing on its concentration (51). Association of the con-
centrations of fetuin-A with bone density and mark-
ers of bone resorption (52) in healthy women without 
diabetes, but not in men (45) suggests the possibility 
of a sexually dimorphic contribution of fetuin-A to the 
development of osteoporosis and bone fractures, and 
probably also there is sexual dimorphism in relation 
fetuin-A and vascular calcification. The presence of low 
bone mineralization, for example in CKD patients, or 
post-menopausal women are associated with the ec-
topic calcification, particularly vascular wall (22, 23). 
It is well documented that estrogen decreases after 
menopause in women. Estrogens deficiency results in 
a sharp increase in bone turnover markers (53). Previ-
ous studies have shown a link between levels of fetuin-A 
and BMD in healthy older women but not in men (45). 
Although the mechanism underlying sexual dimorphism 
according to fetuin-A and biomarkers of bone turnover 
and vascular calcification is still unclear, there may be 
sex-dependent influence of fetuin-A on activity of osteo-
clasts and osteoblasts, or as a secondary effect of sex 
hormones on fetuin-A. Fetuin-A is positively associated 
with estradiol level in women, therefore it is not exclud-
ed that fetuin-A promotes the mineralization of bone in 
post-menopausal women with osteoporosis, which is 
characterized by low levels of estrogen (50).
The postmenopausal women with the most rapid 
bone loss (and therefore the greatest imbalance be-
tween resorption and formation within the bone remod-
eling compartment) have the most rapid rate of artery 
calcifications (54-57). For the above reasons fetuin-A 
is negatively correlated with inflammation parameters 
only in men, but in women it correlates with log (iPTH), 
but not with inflammation.
CONCLUSIONS
1. Patients on maintenance hemodialysis suffer from 
severe calcifications of vascular system.
2. Low serum fetuin-A levels are negatively associ-
ated with calcification parameters, inflammation 
and hyperparathyroidism.
Limitations
The result of the present work should be interpreted 
with caution because of several limitations. First, the 
sample size was small. Second, the cross-sectional na-
ture of the study may also influence the results. Third, 
fetuin-A levels were only assessed at single point in 
time instead of having time-averaged values  and these 
values  are related to bone mineral densitometry pa-
rameters and coronary artery calcification that develop 
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over a long time. In addition, the concentration of fe-
tuin-A may fluctuate, largely depending mainly on the 
status of inflammation and iPTH (21).
Lack of standardization of fetuin-A assays causes 
confusion and discordancy (58). The fetuin-A is an im-
portant inhibitor of extraosseous calcification, but in 
some studies using ELISA assays showed no signifi-
cant correlation between serum fetuin-A and vascular 
calcification in patients with CKD (59). This mismatch 
results is explained by several reasons. One reason 
may be the lack of harmonization of methods for the 
determination of fetuin-A. A commercially available 
various methods for the determination of the protein 
generate different values  (58). Another reason for this 
situation may be the ability of fetuin-A to form the mic-
roparticles, protein and minerals that depending on the 
preparation used for centrifugation of blood which can 
affect the obtained results.
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